Tolterodine



Indications and Reactions:

Role Indications Reactions
Primary
Hypertonic Bladder 80.0%
Urinary Incontinence 20.0%
Gastritis 23.1%
Swollen Tongue 15.4%
Drug Ineffective 7.7%
Food Interaction 7.7%
Inappropriate Schedule Of Drug Administration 7.7%
Memory Impairment 7.7%
Prostate Cancer 7.7%
Somnolence 7.7%
Urinary Retention 7.7%
Vertigo 7.7%
Secondary
Product Used For Unknown Indication 44.8%
Drug Use For Unknown Indication 15.2%
Cardiac Failure 4.8%
Hypertension 4.0%
Chemotherapy 3.2%
Prophylaxis 3.2%
Conjunctivitis 2.4%
Hyperuricaemia 2.4%
Incontinence 2.4%
Pain 2.4%
Prophylaxis Of Nausea And Vomiting 2.4%
Thrombosis Prophylaxis 2.4%
Vomiting 2.4%
Appetite Disorder 1.6%
Atrial Fibrillation 1.6%
Hypertonic Bladder 1.6%
Bladder Disorder 0.8%
Depression 0.8%
Hallucination, Visual 0.8%
Insomnia 0.8%
Completed Suicide 24.1%
Stevens-johnson Syndrome 10.3%
White Blood Cell Count Decreased 6.9%
Bradycardia 3.4%
Drug Rash With Eosinophilia And Systemic Symptoms 3.4%
Drug Toxicity 3.4%
Hypoglycaemia 3.4%
Multiple Drug Overdose Intentional 3.4%
Muscle Spasms 3.4%
Poisoning 3.4%
Somnolence 3.4%
Stupor 3.4%
Suicidal Ideation 3.4%
Suicide Attempt 3.4%
Toxicity To Various Agents 3.4%
Urinary Retention 3.4%
Vertigo 3.4%
Vision Blurred 3.4%
Vomiting 3.4%
Wrong Drug Administered 3.4%
Concomitant
Product Used For Unknown Indication 34.1%
Drug Use For Unknown Indication 22.9%
Rheumatoid Arthritis 5.8%
Depression 5.7%
Hypertension 4.7%
Multiple Sclerosis 3.1%
Pain 3.0%
Prophylaxis 3.0%
Osteoarthritis 2.2%
Hypertonic Bladder 1.9%
Parkinson's Disease 1.6%
Prostate Cancer 1.6%
Bipolar Disorder 1.5%
Benign Prostatic Hyperplasia 1.4%
Blood Cholesterol Increased 1.4%
Constipation 1.4%
Knee Arthroplasty 1.4%
Urinary Tract Infection 1.3%
Anxiety 1.0%
Osteoporosis 1.0%
Vision Blurred 10.8%
Vomiting 8.8%
Sleep Disorder 6.9%
Transient Ischaemic Attack 6.9%
Hallucination 5.9%
Interstitial Lung Disease 5.9%
Weight Increased 5.9%
Dizziness 4.9%
Mobility Decreased 4.9%
Pain In Jaw 3.9%
Pneumonia 3.9%
Rectal Haemorrhage 3.9%
Skin Hyperpigmentation 3.9%
Stupor 3.9%
Urinary Tract Infection 3.9%
White Blood Cell Count Decreased 3.9%
Atrial Fibrillation 2.9%
Drug Toxicity 2.9%
Multiple Sclerosis Relapse 2.9%
Pseudolymphoma 2.9%
Interacting
Drug Use For Unknown Indication 82.6%
Abdominal Pain Upper 8.7%
Bladder Disorder 8.7%
Weight Increased 100.0%